XML 26 R17.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS' EQUITY
9 Months Ended
Mar. 31, 2021
Stockholders' Equity Note [Abstract]  
Shareholders' Equity and Share-based Payments [Text Block]

NOTE 9. STOCKHOLDERS EQUITY

 

Payment of cash dividends is within the discretion of the Company’s board of directors and is dependent on earnings, operations, capital requirements, general financial condition of the Company, and general business conditions. A monthly dividend of $0.0025 per share was paid during fiscal year 2020 and for July 2020 through January 2021. A monthly dividend of $0.0050 per share was paid for February 2021 through March 2021, and as of March 31, 2021, is authorized through June 2021, at which time it will be considered for continuation.

 

The Company has a share repurchase program, approved by the Board of Directors, authorizing the Company to annually purchase up to $2.75 million of its outstanding common shares, as market and business conditions warrant, on the open market in compliance with Rule 10b-18 of the Securities Exchange Act of 1934 through December 31, 2021. The repurchase program has been in place since December 2012, and the Board of Directors has annually renewed the repurchase program each calendar year. The acquired shares may be used for corporate purposes, including shares issued to employees in the Company’s stock-based compensation programs. For the three and nine months ended March 31, 2021, the Company repurchased 19,900 and 35,996 class A shares using cash of $127,000 and $189,000, respectively. For the three and nine months ended March 31, 2020, the Company repurchased 69,420 and 72,820 class A shares using cash of $68,000 and $74,000, respectively.

 

The Company’s stock option plans provide for the granting of class A shares as either incentive or nonqualified stock options to employees and non-employee directors. Options are subject to terms and conditions determined by the Compensation Committee of the Board of Directors. There were 2,000 options outstanding and exercisable at March 31, 2021, at a weighted average exercise price of $2.74. There were no options granted, forfeited, or exercised for the three or nine months ended March 31, 2021. There were no options granted, forfeited, or exercised for the three months ended March 31, 2020. There were 2,000 options forfeited and no options granted or exercised during the nine months ended March 31, 2020.

 

Stock-based compensation expense is measured at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the award’s vesting period. There was no stock-based compensation expense for the three and nine months ended March 31, 2021, or 2020. As of March 31, 2021, and 2020, there was no unrecognized share-based compensation cost related to share-based awards granted under the plans.